Silychristin Derivatives Conjugated with Coniferylalcohols from Silymarin and Their Pancreatic Α-Amylase Inhibitory Title Activity
Total Page:16
File Type:pdf, Size:1020Kb
Silychristin derivatives conjugated with coniferylalcohols from silymarin and their pancreatic α-amylase inhibitory Title activity Author(s) Kato, Eisuke; Kushibiki, Natsuka; Satoh, Hiroshi; Kawabata, Jun Natural Product Research, 34(6), 759-765 Citation https://doi.org/10.1080/14786419.2018.1499639 Issue Date 2020-03-18 Doc URL http://hdl.handle.net/2115/80605 This is an Accepted Manuscript of an article published by Taylor & Francis in Natural Product Research on Rights Mar.18.2020, available online: http://www.tandfonline.com/10.1080/14786419.2018.1499639. Type article (author version) File Information EK_NatProdRes_milk_thistle_w_supplement.pdf Instructions for use Hokkaido University Collection of Scholarly and Academic Papers : HUSCAP *Post-print manuscript This document is the unedited Author's version of a Submitted Work that was subsequently accepted for publication in “Natural Product Research” published by Taylor & Francis after peer review. To access the final edited and published work see https://doi.org/10.1080/14786419.2018.1499639 Graphical abstract 1 RESEARCH ARTICLE Silychristin derivatives conjugated with coniferylalcohols from silymarin and their pancreatic α-amylase inhibitory activity Eisuke Katoa*, Natsuka Kushibikib, Hiroshi Satohc and Jun Kawabataa aDivision of Fundamental AgriScience and Research, Research Faculty of Agriculture, Hokkaido University, Kita-ku, Sapporo, Hokkaido 060-8589, Japan bDivision of Applied Bioscience, Graduate School of Agriculture, Hokkaido University, Kita-ku, Sapporo, Hokkaido 060-8589, Japan cNissei Bio Co. Ltd., Eniwa, Hokkaido, 061-1374, Japan *Corresponding author. Eisuke Kato, 1Division of Fundamental AgriScience and Research, Research Faculty of Agriculture, Hokkaido University, Kita-ku, Sapporo, Hokkaido 060-8589, Japan; Tel/Fax: +81 11 706 2496; e-mail: [email protected] 2 Abstract Silymarin is a mixture of flavonolignans extracted from the fruit of Silybum marianum (milk thistle). The latter is used as a medicinal plant to treat liver and gallbladder disorders. Recently, silymarin has been investigated for its effects against diabetes mellitus, and shown to reduce serum levels of glucose in model animals and in clinical trials. This effect can be explained mainly by the protective effect of silymarin against pancreatic beta-cells, but the involvement of other mechanisms is possible. We demonstrated the α-amylase inhibitory activity of silymarin and investigated the components responsible for this effect. Two major flavonolignans, silibinin and silychristin, did not show inhibition against α-amylase, but two novel silychristin derivatives conjugated with dehydrodiconiferyl alcohol were isolated as the mildly inhibiting components of silymarin. Further analyses indicated the presence of various silychristin derivatives in silymarin that may act synergistically to show α-amylase inhibitory activity. Keywords: silymarin; milk thistle; α-amylase; diabetes mellitus 3 1. Introduction Silymarin is a mixture of flavonoids extracted from the fruits of Silybum marianum (milk thistle). The latter was used by physicians in ancient Greece as a medicinal plant to treat disorders of the liver and gallbladder, as well as to protect liver against chemical and environmental toxins (Kren & Walterova 2005; Rainone 2005). Silymarin is the active component of milk thistle, and its effects against hepatic diseases and non-alcoholic fatty liver disease have been shown in several studies (Federico et al. 2017). Recent studies of silymarin have also reported its neuroprotective (Borah et al. 2013), renoprotective (Shahbazi et al. 2012), immunomodulative (Esmaeil et al. 2017), and cardioprotective effects (Razavi & Karimi 2016), thereby making it an interesting material for research. Recently, silymarin has garnered attention for use against diabetes mellitus (DM) (Kazazis et al. 2014; Voroneanu et al. 2016; Stolf et al. 2017). DM is a metabolic disorder that causes an increase in the glucose level in blood. DM incidence has been increasing rapidly worldwide in recent years. A high amount of glucose in blood vessels leads to an increased risk of various complications. Therefore, the prevention and treatment of DM has been studied widely. The effect of silymarin has been shown in several in vivo experiments against model animals and in clinical trials. Silymarin treatment to streptozotocin- or alloxan-induced DM in rats reduces serum levels of glucose and protects the pancreas (Soto et al. 2010; Amniattalab et al. 2016). Similar treatment with silymarin to partially 4 pancreatectomized rats also reduces serum levels of glucose compared with control, increases the insulin level, and induces the neogenesis of pancreatic beta-cells (C. Soto et al. 2014; Claudia Soto et al. 2014). Moreover, a trial of silymarin in DM patients reduced the levels of fasting blood glucose and glycated hemoglobin (Huseini et al. 2006). These positive effects of silymarin against DM could be attributed to its antioxidant and protective effects on pancreatic beta-cells. However, other effects may also contribute to the anti-DM property of silymarin, and the mechanism of action of silymarin is not completely explored. Digestion of carbohydrates by glycosidases in the gastrointestinal tract is a target of anti-DM medications. Inhibition of α-amylase and α-glucosidase delays the digestion and absorption of carbohydrates, which reduces the rapid increase in the glucose level in blood after food consumption. These digestive enzymes are also studied as common targets of medicinal plants with anti-DM properties (Governa et al. 2018). Here, we investigated if silymarin can modulate α-amylase activity and explored its active constituents. Silymarin showed inhibitory activity against α-amylase. However, silibinin (1) and silychristin (2), the major flavonolignans in silymarin (Csupor et al. 2016), were not shown to be α-amylase inhibitors. Investigation of the active components in silymarin led to the isolation of three novel silychristin derivatives (4–6) and mariamide B (3). 2. Results and Discussion Silymarin showed inhibitory activity against pancreatic α-amylase in a 5 dose-dependent manner at 0.1–5 mg/mL (Figure S1). To ascertain if the major flavonolignans contained in silymarin contribute to α-amylase inhibitory activity, silibinin (1, commercial, Sigma-Aldrich Co.) and silychristin (2, isolated, Cheng et al. 2013) were tested for their activity. However, silibinin (1) showed no inhibitory activity at <1.0 mg/mL, and nor did silychristin (2). Thus, activity-guided separation was undertaken to elucidate the component in silymarin with α-amylase inhibitory activity. Silymarin was partitioned between solvents (water, 1-butanol, ethyl acetate). The ethyl-acetate layer was separated twice by silica-gel column chromatography to obtain the active fraction (AF). However, further separation of the AF by the reverse-phase column resulted in dispersed activity within broad range of fractions. This finding suggested that several compounds contribute to the α-amylase inhibitory activity of silymarin. Next, we focused on analyzing the AF to explore the type of compound that contributes to α-amylase inhibition. The fractions obtained after reverse-phase column chromatography were analyzed by high-performance liquid chromatography (HPLC) and the major peaks were collected. The peaks were analyzed by nuclear magnetic resonance (NMR) and mass spectroscopy (MS) to elucidate their structures and these compounds were numbered 3–6 (Figure 1). Compound 3 was obtained as a mixture which appeared as two peaks upon HPLC. These two peaks converted readily to each other and a single peak could not be 6 obtained, so they were analyzed as a mixture to elucidate their structures. Proton (1H)-NMR suggested that the mixtures were cis/trans stereoisomers resulting from isomerization of an alkene moiety (trans isomer: 7.45/6.44 ppm, J = 15.5 Hz; cis isomer: 6.64/5.85 ppm, J = 12.7 Hz). Additional NMR procedures (13C, correlated spectroscopy (COSY), heteronuclear multiple quantum coherence (HSQC) and heteronuclear multiple bond correlation (HMBC), Figure S4-S6) and comparison with the reported value (Choudhary et al. 2008; Qin et al. 2017) of predicted structures revealed compound 3 to be the mixture of mariamide B and its trans-isomer. Compound 4 was analyzed by high resolution (HR)-electrospray ionization + (ESI)-MS to reveal the molecular formula C35H32O13 (found m/z 683.17583 [M+Na] , + 1 C35H32O13Na requires 683.17351). H-NMR showed a similar spectrum to that of silychristin (2) but with additional signals indicating condensation of coniferyl alcohol. The predicted structure with the determined molecular formula did not correspond to any of the structures reported previously, thereby suggesting a novel compound. Careful analyses of compound 4 with 13C-NMR, COSY, HSQC, and HMBC showed its structure (Table S1, Figure S7-S10)., which was named coniferylsilychristin (4) Compounds 5 and 6 were analyzed by HR-ESI-MS to reveal the molecular + formula C45H42O15 (compound 5: found m/z 845.24252 [M+Na] ; compound 6: found + + 1 m/z 845.24139 [M+Na] ; C45H42O15Na requires 845.24159). H-NMR of compounds 5 and 6 showed a similar spectrum to that of silychristin (2) but with additional signals suggesting the conjugation of dehydrodiconiferyl alcohol, and compounds 5 and 6 were presumed to be novel compounds. Analyses of compounds 5 and 6 by 13C-NMR, COSY, HSQC, and HMBC revealed their structures (Table S2,S3, Figure S11-S18), which were 7 named